Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benproperine is a small molecule antitussive (cough suppressant) used for the symptomatic relief of acute and dry cough. It is marketed in several countries in Central America and Europe as phosphate or pamoate salts and is available in tablet or syrup form. Benproperine acts centrally to suppress the cough reflex; its mechanism of action differs from that of opioid antitussives like codeine. Recent research suggests it may also have anticancer properties by inducing autophagy arrest via AMPK/mTOR signaling and interfering with RAB11A-mediated autophagosome–lysosome fusion in pancreatic cancer cells[1][2][5]. The drug belongs to the diphenylmethane class of organic compounds.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Benproperine.